Skip to main content
Premium Trial:

Request an Annual Quote

Phenomenex, Tecan Ink Marketing Deal for SPE Sample Prep Solutions

NEW YORK (GenomeWeb) – Phenomenex and Tecan Group on Tuesday announced a co-marketing agreement for Phenomenex's automated solid phase extraction sample preparation solutions. 

The partners will co-market the Phenomenex Strata and Strata-X SPE sorbents adapted to Tecan's Freedom EVO series of robotic workstations. The solution, they said, is geared to high-throughput customers in pharmaceutical research, and clinical and food testing using mass spectrometry methods. 

Tecan will provide the instruments and automation support, while Phenomenex will provide the extraction chemistries. It also will work with the PhenoLogix group, a full-service analytical support laboratory within Phenomenex, on applications and method development. 

The firms said that Phenomenex Strata and Strata-X SPE sorbents remove unwanted contaminants, such as phospholipids, and are available in a variety of selectivities to cover a range of analytes. Performing solid phase extraction on Tecan's instruments in combination with optimized conditions from PhenoLogix "will decrease implementation efforts in the lab, increase throughput while reducing human error, and enable sample traceability for regulated environments," Phenomenex and Tecan said. 

Tecan Head of Clinical Diagnostics James O' Brien said in a statement that the agreement will enable Tecan to expand its reach in the high-volume solid phase extraction space. 

"The experts at Phenomenex and PhenoLogix have enhanced our knowledge of chromatography and enabled us to bring to market a product for mid- to high-throughput laboratories that increases the [return on investments] of their high-capital investment in mass spectrometry detection systems," O' Brien said.  

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.